News for Atai Life Sciences N.V. (ATAI)

- The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (m

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are going to take a look at where Atai Life Sciences N.V.

NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences ( ATAI) (”œatai” or ”œCompany”), a clinical-stage biopharmaceutical company ai

ATAI Life Sciences announces a $55M stock offering to fund clinical programs and corporate needs.

Canada-based Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company is up over 74 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Thursday. Shares of The Trade Desk, Inc. TTD fell sharply in today's...

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (”œatai” or ”œCompany”), a clinical-stage biopharmaceutical com

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences ( ATAI) (”œatai” or ”œCompany”), a clinical-stage biopharmaceutical company fo

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences ( ATAI) (”œatai” or ”œCompany”), a clinical-stage biopharmaceutical company fo

atai Life Sciences (ATAI) announces a $55M stock offering to fund clinical development and operations.

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

This is our list of the best penny stocks to watch, based on a review of stocks that had positive performance over the last 30 days.

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients. Read more on ATAI stock update.

**media[511571]**

- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief S

Atai Life Sciences N.V. (ATAI) experienced a significant stock movement with a 5.04% rise, reaching $1.25 per share. The trading volume was 791,815 shares, with

Atai Life Sciences N.V. (ATAI) experienced a significant stock drop of 5.07%, with shares priced at $1.41 and a trading volume of 597,044 shares. The turnover r

ATAI Life Sciences N.V. (ATAI) experienced a significant stock drop of 5.52%, with shares priced at $1.54. The trading volume reached 732,560 shares, reflecting

ATAI Life Sciences N.V. (ATAI) saw its stock price fall by 5.03%, trading at $1.61 per share with a volume of 689,255 shares. The stock's turnover rate was 0.41